CN105050613A - 降低与心脏衰竭相关的风险和与其相关的因素的方法 - Google Patents

降低与心脏衰竭相关的风险和与其相关的因素的方法 Download PDF

Info

Publication number
CN105050613A
CN105050613A CN201380067076.XA CN201380067076A CN105050613A CN 105050613 A CN105050613 A CN 105050613A CN 201380067076 A CN201380067076 A CN 201380067076A CN 105050613 A CN105050613 A CN 105050613A
Authority
CN
China
Prior art keywords
subject
heart failure
agents
peptide
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067076.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
哈尼·N·萨巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Henry Ford Health System
Original Assignee
Stealth Peptides International Inc
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc, Henry Ford Health System filed Critical Stealth Peptides International Inc
Priority to CN201910384895.6A priority Critical patent/CN110193077A/zh
Publication of CN105050613A publication Critical patent/CN105050613A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
CN201380067076.XA 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法 Pending CN105050613A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910384895.6A CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US61/716,867 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US61/822,752 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26
US61/839,743 2013-06-26
US61/839,750 2013-06-26
PCT/US2013/066228 WO2014066419A2 (en) 2012-10-22 2013-10-22 Methods for reducing risks associated with heart failure and factors associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910384895.6A Division CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Publications (1)

Publication Number Publication Date
CN105050613A true CN105050613A (zh) 2015-11-11

Family

ID=50545459

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380067076.XA Pending CN105050613A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法
CN201910384895.6A Pending CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910384895.6A Pending CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Country Status (12)

Country Link
US (4) US20150246092A1 (enExample)
EP (4) EP4397314B1 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN105050613A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414472A (zh) * 2016-06-24 2019-03-01 南加利福尼亚大学 Mentsh类似物作为用于糖尿病、肥胖及其相关疾病和并发症的治疗剂

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
US9687519B2 (en) * 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
SG10201912128SA (en) 2017-02-01 2020-02-27 Univ Yale Treatment of diuretic resistance
WO2019136312A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A3 (en) * 2003-02-04 2005-04-14 Cornell Res Foundation Inc Methods for preventing mitochondrial permeability transition
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR20130001318A (ko) * 2002-07-19 2013-01-03 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
CN104056248A (zh) * 2008-02-26 2014-09-24 康奈尔大学 用于防止和治疗急性肾损伤的方法
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2013506696A (ja) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
AU2010324739B2 (en) * 2009-11-24 2016-05-05 H. Lundbeck A/S. Antibodies to IL-6 and use thereof
AU2010339414A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2879689A4 (en) * 2012-08-02 2015-12-16 Stealth Peptides Int Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
EP3287172A1 (en) * 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
US9884085B2 (en) * 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A3 (en) * 2003-02-04 2005-04-14 Cornell Res Foundation Inc Methods for preventing mitochondrial permeability transition
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
姚陈一: "冠状动脉旁路移植术后低氧血症相关危险因素分析", 《国际心血管病杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414472A (zh) * 2016-06-24 2019-03-01 南加利福尼亚大学 Mentsh类似物作为用于糖尿病、肥胖及其相关疾病和并发症的治疗剂

Also Published As

Publication number Publication date
MX2015005102A (es) 2016-02-09
EP3586862A1 (en) 2020-01-01
US20230190859A1 (en) 2023-06-22
KR20160009008A (ko) 2016-01-25
AU2013334788A1 (en) 2015-06-04
US20150246092A1 (en) 2015-09-03
WO2014066419A3 (en) 2014-06-12
BR112015009072A2 (pt) 2017-07-04
US20250255929A1 (en) 2025-08-14
EP4397314A1 (en) 2024-07-10
JP2016503397A (ja) 2016-02-04
JP2018109012A (ja) 2018-07-12
AU2018206766A1 (en) 2018-08-09
NI201500057A (es) 2015-07-16
EP4397314B1 (en) 2025-12-03
EP4005582A1 (en) 2022-06-01
EP2908839A4 (en) 2016-06-15
US20200360462A1 (en) 2020-11-19
WO2014066419A2 (en) 2014-05-01
CA2889155A1 (en) 2014-05-01
EP2908839A2 (en) 2015-08-26
CN110193077A (zh) 2019-09-03
JP2019194193A (ja) 2019-11-07
PE20151434A1 (es) 2015-10-16
EP3586862B1 (en) 2021-12-08
HK1213799A1 (en) 2016-07-15
EP2908839B1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
US20250255929A1 (en) Methods for reducing risks associated with heart failure and factors associated therewith
JP7072692B2 (ja) バース症候群の予防または治療のための方法及び組成物
US11312993B2 (en) Methods and compositions for detecting and diagnosing diseases and conditions
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40115529A (en) Treatment of left ventricular remodeling
HK1213799B (en) Methods for reducing risks associated with heart failure and factors associated therewith
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151111